ARC-7
10 Nov 2020
Trial Summary
This Randomized Phase 2 Open-label Study will Evaluate the Safety and Efficacy of Zimberelimab (AB122) Monotherapy, AB154 in Combination with Zimberelimab, and AB154 in Combination with Zimberelimab and AB928 in Front-line, PD-L1 Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer.
Acronym:
ARC-7
ACTRN/NCT /ethics:
NCT04262856
Scientific title:
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer.
Sponsor / Cooperative group:
Arcus Biosciences, Inc.
Trial & Patient Characteristics
| Cancer Type | Lung & mesothelioma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2020-05-28 |
| Anticipated End Date | 2023-06-23 |
Participating Hospitals
| Hospital | Calvary Central Districts Hospital |
|---|---|
| Clinical Trial Coordinator | Julie Rowe |
| julie.rowe@calvarycare.org.au | |
| Phone | 08 8239 9536 |
| Principal Investigator | Dr Rohit Joshi |
| Recruitment Status | Recruiting |